Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-09-02 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange's news service. The content is structured as a 'TR-1: Standard form for notification of major holdings' concerning Nigel James Theobald's change in shareholding percentage (crossing a threshold from 11.16% to 10.97%) in N4 Pharma PLC on September 2, 2020. This type of filing, which reports changes in significant share ownership, directly corresponds to the definition for Major Shareholding Notification (MRQ). Although it is an RNS release, the specific content dictates the more precise classification of MRQ over the general RNS fallback.
2020-09-02 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement released via RNS (Regulatory News Service) on September 2, 2020. The core content explicitly states the 'Total Voting Rights' of the company as of the announcement date (154,730,349 shares). This information is crucial for shareholders to calculate their required notifications under FCA Disclosure Guidance and Transparency Rules. This type of announcement, which provides a specific, periodic regulatory metric without being a full financial report (like 10-K or IR) or a management change, fits best under the general 'Regulatory Filings' category (RNS) as it is a standard regulatory disclosure required by the exchange, although it is related to share capital structure. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or a Share Issue (SHA), but rather a mandatory disclosure of the total denominator for voting rights.
2020-09-02 English
Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that the CEO will present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference. It contains standard press release formatting, contact information, an 'About' section, and 'Forward-Looking Statements'. This type of announcement, detailing executive participation in an external investor event, is typically classified as an Investor Presentation (IP) or sometimes an Earnings Release (ER) if it coincides with results. However, since the core purpose is to announce a presentation/overview at an investment conference, 'Investor Presentation (IP)' is the most fitting category, as it relates directly to investor outreach and presentation materials, even if this specific document is just the announcement of the presentation.
2020-09-02 English
Technology Transfer and Manufacturing Contract
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 5453X' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority (FCA) to act as a Primary Information Provider. The content itself is an announcement regarding a 'Technology Transfer and Manufacturing Contract' between N4 Pharma and Ardena. This type of material—a specific, material corporate update released via the official regulatory news service (RNS) that doesn't fit neatly into financial reports (10-K, IR), earnings (ER), or shareholder meetings (AGM-R, DEF 14A)—is best classified as a general Regulatory Filing or announcement. Since RNS is explicitly mentioned as the distribution channel and the content is a material, non-standard announcement, the most appropriate code is RNS, which serves as the general regulatory announcement fallback.
2020-09-01 English
Exercise of Warrants and Issue of Equity
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the 'Exercise of Warrants and Issue of Equity,' which results in a change to the total issued share capital (154,730,349 Ordinary Shares). This type of announcement regarding share issuance and capital structure changes, distributed via the RNS system, most closely aligns with the 'Share Issue/Capital Change' definition (SHA). Although it is an RNS filing, SHA is more specific than the general RNS fallback.
2020-08-26 English
Verona Pharma plc: Grant of RADSUs and PDMR Dealings
Share Issue/Capital Change Classification · 1% confidence The document explicitly details the 'Grant of RADSUs' (Restricted American Depositary Share Units) to 'persons discharging managerial responsibilities' (PDMRs) and other employees, including the CEO and CFO. This type of filing, which reports personal share transactions by company directors and executives, directly corresponds to the definition of Director's Dealing. The structure, including sections for 'Details of the person discharging managerial responsibilities' and 'Nature of the transaction: Grant of RADSUs', confirms this classification. This is not an earnings release, annual report, or a general regulatory announcement, but a specific insider transaction disclosure.
2020-08-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.